Charles Schwab Investment Management Inc. Has $2.26 Million Stock Position in Anika Therapeutics, Inc. (NASDAQ:ANIK)

Charles Schwab Investment Management Inc. trimmed its holdings in Anika Therapeutics, Inc. (NASDAQ:ANIK) by 8.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 137,462 shares of the biotechnology company’s stock after selling 12,494 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Anika Therapeutics were worth $2,263,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. R Squared Ltd bought a new stake in shares of Anika Therapeutics in the fourth quarter worth $27,000. Los Angeles Capital Management LLC grew its position in shares of Anika Therapeutics by 9.1% in the fourth quarter. Los Angeles Capital Management LLC now owns 11,700 shares of the biotechnology company’s stock valued at $193,000 after purchasing an additional 980 shares during the last quarter. HighTower Advisors LLC boosted its position in shares of Anika Therapeutics by 11.3% in the third quarter. HighTower Advisors LLC now owns 15,883 shares of the biotechnology company’s stock valued at $387,000 after acquiring an additional 1,615 shares during the period. Jane Street Group LLC raised its position in shares of Anika Therapeutics by 54.1% in the third quarter. Jane Street Group LLC now owns 24,351 shares of the biotechnology company’s stock valued at $601,000 after buying an additional 8,550 shares in the last quarter. Finally, FMR LLC increased its holdings in Anika Therapeutics by 25.3% in the 3rd quarter. FMR LLC now owns 24,721 shares of the biotechnology company’s stock valued at $611,000 after buying an additional 4,996 shares during the period. 91.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have commented on ANIK shares. StockNews.com raised Anika Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, March 13th. Barrington Research reduced their price objective on shares of Anika Therapeutics from $25.00 to $20.00 and set an “outperform” rating for the company in a research report on Thursday, March 13th.

Anika Therapeutics Trading Down 2.5 %

Shares of NASDAQ:ANIK opened at $15.11 on Friday. Anika Therapeutics, Inc. has a 1-year low of $14.95 and a 1-year high of $29.12. The stock has a market cap of $214.20 million, a PE ratio of -2.27 and a beta of 0.95. The stock’s fifty day simple moving average is $16.84 and its two-hundred day simple moving average is $18.88.

Anika Therapeutics (NASDAQ:ANIK) last posted its quarterly earnings results on Wednesday, March 12th. The biotechnology company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.13). Anika Therapeutics had a negative net margin of 59.40% and a negative return on equity of 2.22%. The company had revenue of $30.60 million for the quarter, compared to the consensus estimate of $29.00 million. On average, sell-side analysts forecast that Anika Therapeutics, Inc. will post -0.84 earnings per share for the current fiscal year.

About Anika Therapeutics

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.